Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
Participants were broken into two cohorts. The first cohort received one of three doses of PCRX-201. The second cohort received concurrent pretreatment with an intraarticular corticosteroid ...
Knee problems tend to flare up as you age – an orthopedic specialist explains available treatment options
Injuries and osteoarthritis of the knee are common. Fortunately, there are many ways to prevent and treat knee pain.
Pacira announces 104-week safety, efficay data for PCRX-201
BioSciences announced new data demonstrating its gene therapy for osteoarthritis candidate, PCRX-201, provided sustained ...
ScienceAlert10h
Not Just Weight Loss: 8 Conditions Drugs Like Wegovy Might Treat
There has been a lot of excitement since the launch. Not only is the drug extremely effective (people lose about 15 percent ...
Eight Conditions Weight-Loss Jabs Might Be Beneficial For
The weight-loss jab Wegovy made its debut on June 4 2021 . It was the first new weight-loss drug to be approved by the US ...
Armed robbery in Revesby21h
Eight Conditions Weight-Loss Jabs Could Aid
The weight-loss jab Wegovy made its debut on June 4 2021 . It was the first new weight-loss drug to be approved by the US Food and Drug ...
Phase 3 study finds inebilizumab effective for immunoglobulin G4–related disease
An international, phase 3 clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare disease that can cause debilitating symptoms.
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.